NCT02754479 is a NA clinical trial of Nd:YAG laser in Spider Veins, sponsored by Cutera Inc..

Who is sponsoring NCT02754479?

NCT02754479 is sponsored by Cutera Inc..

What drugs are being tested in NCT02754479?

Interventions in NCT02754479: Nd:YAG laser.

What condition does NCT02754479 study?

NCT02754479 studies Spider Veins.

Is NCT02754479 still recruiting?

NCT02754479 is currently completed. Last updated 9 May 2023.

Are results published for NCT02754479?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-05-09 · How we verify

NCT02754479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Evaluation of the Treatment of Spider Veins on the Ankles

Completed NA Results posted Last updated 9 May 2023

What this trial tests

NA trial testing Nd:YAG laser in Spider Veins in 4 participants. Completed in 15 March 2017.

Timeline

10 June 2016

Primary endpoint
22 December 2016

15 March 2017

Quick facts

Lead sponsor	Cutera Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	10 June 2016
Primary completion	22 December 2016
Estimated completion	15 March 2017
Sites	1 location across United States

Drugs / interventions tested

Nd:YAG laser

Conditions studied

Spider Veins — all drugs for Spider Veins →

Sponsor

Cutera Inc.

Who can join

Adults 20 to 75, any sex, with Spider Veins. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles Primary · Four weeks post final laser treatment.

Improvement in treated ankle spider veins at 4 weeks post final laser treatment (compared to baseline) as assessed by a blinded evaluators Physician Global Assessment Scale score (Min=0; 4= Max). Higher Score Indicates Better Outcome.

Group	Value	95% CI
Laser Treatments	3.7	± 0.6

Subject Satisfaction With Improvement in Treated Spider Veins on the Ankles Secondary · Four weeks post final laser treatment

Subject satisfaction with improvement in spider veins on the ankles as assessed using the Subject Satisfaction Assessment scale (Min=1, Max=5) at 4 weeks post final treatment. Higher score indicates better outcome.

Group	Value	95% CI
Laser Treatments	4.3	± 1.2

Adverse events — posted to ClinicalTrials.gov

Time frame: Treatment through 4-weeks post final treatment, up to 6 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Laser Treatments

Serious: 0/3 (0%)

Deaths: 0/3

Other adverse events (8 terms — click to expand)

Reaction	System	Laser Treatments
Erythema	Skin and subcutaneous tissue disorders	—
Post Inflammatory Hyperpigmentation	Skin and subcutaneous tissue disorders	—
Discomfort	Skin and subcutaneous tissue disorders	—
Darkening of Vessel	Skin and subcutaneous tissue disorders	—
Edema	Skin and subcutaneous tissue disorders	—
Purpura	Skin and subcutaneous tissue disorders	—
Crusting	Skin and subcutaneous tissue disorders	—
Nodule	Skin and subcutaneous tissue disorders	—

Data from ClinicalTrials.gov NCT02754479 adverse events section.

Sponsor's own description

To evaluate the safety and effectiveness of the Excel V system for the treatment of lower extremity spider veins on the ankles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Nd:YAG laser

Trials testing the same drug.

NCT07415434 — Laser-assisted Pontic Site Soft Tissue Healing Prior to Fixed Partial Denture Rehabilitation · NA · completed
NCT06442553 — New Generation Low Level Laser Effect in Myofacial Pain Syndrome · NA · completed
NCT04694222 — Use of Laser Assisted New Attachment Procedure and Low Level Laser Therapy for Periodontitis Patients · NA · completed

Other Cutera Inc. trials

Trials by the same sponsor.

NCT06469398 — A Post Market Device Study for the Treatment of Acne · NA · active not recruiting
NCT04695691 — A Device Study for the Treatment of Acne · NA · completed
NCT03782545 — Multi-Center Pilot Study of Cutera truSculpt Device · NA · completed
NCT03424148 — Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment · NA · completed
NCT03424161 — Multi-Center, Clinical Evaluation of the Cutera Secret RF Device · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02754479 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cutera Inc.
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02754479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing